A share price of Transmedics Group Inc [TMDX] is currently trading at $143.80, up 0.13%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TMDX shares have lost -0.53% over the last week, with a monthly amount drifted -4.76%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on September 24, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $200. Previously, Needham started tracking the stock with Buy rating on August 21, 2024, and set its price target to $208. On June 06, 2024, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $161 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $151 on June 04, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $95 as its price target on March 28, 2024. In a note dated August 02, 2022, JP Morgan upgraded an Overweight rating on this stock but restated the target price of $48.
Transmedics Group Inc experienced fluctuations in its stock price throughout the past year between $36.42 and $177.37. Currently, Wall Street analysts expect the stock to reach $162.25 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $143.80 at the most recent close of the market. An investor can expect a potential return of 12.83% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 358.76M which represents 117.87% growth. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at 0.0%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.02 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 141.99 points at the first support level, and at 140.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 145.34, and for the 2nd resistance point, it is at 146.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 9.37. Further, the Quick Ratio stands at 8.48, while the Cash Ratio is 6.68. Considering the valuation of this stock, the price to sales ratio is 13.37, the price to book ratio is 25.23 and price to earnings (TTM) ratio is 4028.01.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Oct 01 ’24 when 2958.0 shares were sold. President & CEO, Hassanein Waleed H completed a deal on Sep 16 ’24 to sell 8625.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 2960.0 shares on Sep 03 ’24.
